It is noteworthy that these criteria were primarily developed based on the clinical characteristics observed in families harboring MLH1 and MSH2 genetic variants and may not fully capture the cancer phenotypes associated with PMS2 genetic variants. The gene discussed is MSH2; the disease is cancer.